Eosinophil Count and Serum Immunoglobulin E Levels in Atopic Dermatitis: Analysis of Upadacitinib Phase 2 Study Findings
Lisa A. Beck(University of Rochester Medicine), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Jonathan I. Silverberg(George Washington University), Kristie M. Grebe(AbbVie (United States)), Feng Hong(AbbVie (United States)), Julie Parmentier(AbbVie (United States)), Henrique D. Teixeira(AbbVie (United States))
Cited by 7
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k